miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 6, 2014, Pages 884-891

  Yang, Mifang ^a   Shan, Xia ^b   Zhou, Xin ^c   Qiu, Tianzhu ^c   Zhu, Wei ^c   Ding, Yin ^d   Shu, Yongqian ^c   Liu, Ping ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NANJING UNIVERSITY   (China)

Author keywords

BCL2; Cisplatin resistance; IGF1R IRS1 pathway; miR 1271; mTOR

Indexed keywords

CISPLATIN; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 1271; PROTEIN BCL 2; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MIRN1271 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

3' UNTRANSLATED REGION; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER RESISTANCE; CELL CULTURE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GASTRIC CANCER CELL LINE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LUCIFERASE ASSAY; MTT ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; STOMACH NEOPLASMS; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, IGF TYPE 1; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84904136606     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140528161318     Document Type: Article

References (28)

1. Zhang, D.; Fan, D. Multidrug resistance in gastric cancer: Recent research advances and ongoing therapeutic challenges. Expert Rev. Anticancer Ther., 2007, 7(10), 1369-1378.
2. Giovannetti, E.; Erozenci, A.; Smit, J.; Danesi, R.; Peters G.J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol., 2012, 81(2), 103-122.
3. Wilting, R.H.; Dannenberg, J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Update, 2012, 15(1-2), 21-38.
4. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A.; Wong, K.K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drug- tolerant state in cancer cell subpopulations. Cell, 2010, 141(1), 69-80.
5. Ozaki, K.; Kishikawa, F.; Tanaka, M.; Sakamoto, T.; Tanimura, S.; Kohno, M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci., 2008, 99(2), 376-384.
6. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205(2), 275-292.
7. Kelland, L.R.; Sharp, S.Y.; O'Neill, C.F.; Raynaud, F.I.; Beale, P.J.; Judson, I.R. Mini-review: Discovery and development of platinum complexes designed to circumvent cisplatin resistance. J. Inorg. Biochem., 1999, 77(1-2), 111-115.
8. Fulda, S.; Debatin, K.M. Modulation of apoptosis signaling for cancer therapy. Arch. Immunol. Ther. Exp. (Warsz), 2006, 54(3), 173-175.
9. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5), 843-854.
10. Lynam-Lennon, N.; Maher, S.G.; Reynolds, J.V. The roles of microRNA in cancer and apoptosis. Biol. Rev. Camb. Philos. Soc., 2009, 84(1), 55-71.
11. Wang, Y.; Lee, C.G. MicroRNA and cancer--focus on apoptosis. J. Cell Mol. Med., 2009, 13(1), 12-23.
12. Xia, L.; Zhang, D.; Du, R.; Pan, Y.; Zhao, L.; Sun, S.; Hong, L.; Liu, J.; Fan, D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer, 2008, 123, 372-379.
13. Zhu, W.; Xu, H.; Zhu, D.; Zhi, H.; Wang, T.; Wang, J.; Jiang, B.; Shu, Y.; Liu, P. MiR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother. Pharmacol., 2012, 69(3), 723-731.
14. Zhu, W.; Shan, X.; Wang, T.S.; Shu, Y.Q.; Liu, P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer, 2010, 127(11), 2520-2529.
15. Bourguignon, L.Y.; Spevak, C.C.; Wong, G.; Xia, W.; Gilad, E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem., 2009, 284(39), 26533-26546.
16. Li, Y.; Li, W.; Yang, Y.; Lu, Y.; He, C.; Hu, G.; Liu, H.; Chen, J.; He, J.; Yu, H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res., 2009, 1286, 13-18.
17. Yang, S.M.; Huang, C.; Li, X.F.; Yu, M.Z.; He, Y.; Li, J. MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology, 2013, 306, 162-168.
18. Zhao, D.S.; Chen, Y.; Jiang, H.; Lu, J.P.; Zhang, G.; Geng, J.; Zhang, Q.; Shen, J.H.; Zhou, X.; Zhu, W.; Shan, Q.J. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc. Pathol., 2013, 22(6), 444-450.
19. Ge, J.; Chen, Z.; Wu, S.; Chen, J.; Li, X.; Li, J.; Yin, J.; Chen, Z. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion, 2009, 80(3), 148-158.
20. Hopkins, A.; Crowe, P.J.; Yang, J.L. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J. Cancer Res. Clin. Oncol., 2010, 136(5), 639-650.
21. Murayama, T.; Inokuchi, M.; Takagi, Y.; Yamada, H.; Kojima, K.; Kumagai, J.; Kawano, T.; Sugihara, K. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br. J. Cancer, 2009, 100(5), 782-788.
22. Yu, G.; Wang, J.; Chen, Y.; Wang, X.; Pan, J.; Li, G.; Jia, Z.; Li, Q.; Yao, J.C.; Xie, K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin. Cancer Res., 2009, 15(5), 1821-1829.
23. Zhu, D.X.; Zhu, W.; Fang, C.; Fan, L.; Zou, Z.J.; Wang, Y.H.; Liu, P.; Hong, M.; Miao, K.R.; Liu, P.; Xu, W.; Li, J.Y. MiR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis, 2012, 33(7), 1294-1301.
24. Eckstein, N.; Servan, K.; Hildebrandt, B.; Politz, A.; Von Jonquières, G.; Wolf-Kummeth, S.; Napierski, I.; Hamacher, A.; Kassack, M.U.; Budczies, J.; Beier, M.; Dietel, M.; Royer-Pokora, B.; Denkert, C.; Royer, H.D. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res., 2009, 69(7), 2996-3003.
25. Morin, R.D.; O'Connor, M.D.; Griffith, M.; Kuchenbauer, F.; Delaney, A.; Prabhu, A.L.; Zhao, Y.; McDonald, H.; Zeng, T.; Hirst, M.; Eaves, C.J.; Marra, M.A. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res., 2008, 18(4), 610-621.
26. Jensen, K.P.; Covault, J. Human miR-1271 is a miR-96 paralog with distinct non-conserved brain expression pattern. Nucleic Acids Res., 2011, 39(2), 701-711.
27. Nurul-Syakima, A.M.; Yoke-Kqueen, C.; Sabariah, A.R.; Shiran, M.S.; Singh, A.; Learn-Han, L. Differential microRNA expression and identification of putative miRNA targets and pathways in head and neck cancers. Int. J. Mol. Med., 2011, 28(3), 327-336.
28. Maurel, M.; Jalvy, S.; Ladeiro, Y.; Combe, C.; Vachet, L.; Sagliocco, F.; Bioulac-Sage, P.; Pitard, V.; Jacquemin-Sablon, H.; Zucman-Rossi, J.; Laloo, B.; Grosset, C.F. A functional screening identifies five microRNAs controlling glypican-3: Role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013, 57(1), 195-204.